Class certification conundrum in the pharma field
Agreements between branded and generic drug makers for the latter to stay off the market for a certain period have become the basis for hundreds of “pay for delay” antitrust cases in the US; one observer opines that there may be more pending now than ever before.
Subscribe to Global Competition Review
Subscribe and start reading now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10